New chelation therapies and emerging chelating drugs for the treatment of iron overload
Author:
- 27 February 2006
- journal article
- Published by Informa Healthcare in Expert Opinion on Emerging Drugs
- Vol. 11 (1) , 1-5
Abstract
(2006). New chelation therapies and emerging chelating drugs for the treatment of iron overload. Expert Opinion on Emerging Drugs: Vol. 11, No. 1, pp. 1-5. doi: 10.1517/14728214.11.1.1Keywords
This publication has 14 references indexed in Scilit:
- Advances in Iron Overload Therapies. Prospects for Effective Use of Deferiprone (L1), Deferoxamine, the New Experimental Chelators ICL670, GT56-252, L1NAll and their CombinationsCurrent Medicinal Chemistry, 2005
- Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonanceBritish Journal of Haematology, 2004
- Benefits and Risks of Deferiprone in Iron Overload in Thalassaemia and Other ConditionsDrug Safety, 2003
- Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemiaThe Lancet, 2002
- Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia RegisterThe Lancet, 2000
- Ultrastructural Pathology of the Heart in Patients with ß-Thalassaemia MajorUltrastructural Pathology, 2000
- Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiproneBritish Journal of Haematology, 1995
- Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.BMJ, 1987
- Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-onesInorganica Chimica Acta, 1987
- The Biochemistry of Desferrioxamine and its Relation to Iron MetabolismAnnals of the New York Academy of Sciences, 1964